EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis

Gaia Ninatti, Pietro Scilipoti, Cristiano Pini, Francesco Barletta, Mattia Longoni, Fabrizia Gelardi, Martina Sollini, Giorgio Gandaglia, Mike Sathekge, Francesco Montorsi, Arturo Chiti, Alberto Briganti

Theranostics · 20.02.2025 · 15 (8) · 3386-3399

DOI: 10.7150/thno.106574 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Theranostics, erschienen am 20.02.2025. Verfasst von Gaia Ninatti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, IRCCS San Raffaele Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Actinium, Alpha Particles, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 34-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Metastatic prostate cancer in the castration-resistant (mCRPC) setting remains challenging to treat. Prostate-specific membrane antigen (PSMA)-targeted alpha therapy (TAT) is emerging as a promising option. We aimed to systematically review the efficacy and safety of PSMA-TAT in patients with prostate cancer.

Methods

A comprehensive search of PubMed/MEDLINE and EMBASE databases was conducted up to October 2024, adhering to the PRISMA guidelines. Selected studies were original research articles evaluating the efficacy and/or safety of PSMA-TAT including at least 10 patients. The outcomes measured included any prostate-specific antigen (PSA) response, ≥50% PSA reduction (PSA50), progression-free survival (PFS), overall survival (OS), and adverse events. PSA50 was pooled using a random-effects model, incorporating individual patient data on PSA50 and previous lines of treatment.

Results

Eighteen studies involving 1,155 patients met the inclusion criteria. The majority included heavily pre-treated patients. The most commonly employed radiopharmaceutical was [225Ac]Ac-PSMA-617, in 15 studies. The pooled PSA50 response rate was 65% [95% Confidence interval (CI), 57-72%] with a moderate level of heterogeneity (I² = 81.17%, p < 0.001). Pooled response rates in patients who received none, one, and more than one prior line of treatment were 82% (95% CI, 73-90%), 72% (95% CI, 56-85%), and 55% (95% CI, 48-63%), respectively. PFS varied from 3 to 15 months, and OS from 8 to 31 months. Adverse events were predominantly mild (grades 1-2); severe adverse events (≥ grade 3) included anaemia (11%) and thrombocytopenia (6%).

Conclusion

PSMA-TAT holds promising efficacy and an acceptable safety profile for treating metastatic prostate cancer. Randomised controlled trials are needed to optimise treatment protocols toward the implementation of PSMA-TAT into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ActiniumAlpha ParticlesAntigens, SurfaceGlutamate Carboxypeptidase IIProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsHumansMaleNeoplasm MetastasisProstate-Specific AntigenProstatic NeoplasmsTreatment Outcome

Stichwörter der Autor:innen

PSA responsePSMAmCRPCprostate cancertargeted alpha therapy

Substanzen

ActiniumActinium-225Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIProstate-Specific AntigenRadiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine Department, IRCCS San Raffaele Hospital, Milan, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Italy.
  • Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.
  • Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa.

Zitieren

APA

Ninatti, G., Scilipoti, P., Pini, C., Barletta, F., Longoni, M., Gelardi, F., Sollini, M., Gandaglia, G., Sathekge, M., Montorsi, F., Chiti, A., & Briganti, A. (2025). Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis. Theranostics, 15(8), 3386-3399. https://doi.org/10.7150/thno.106574

Vancouver

Ninatti G, Scilipoti P, Pini C, Barletta F, Longoni M, Gelardi F, et al. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis. Theranostics. 2025;15(8):3386-3399. doi:10.7150/thno.106574

BibTeX
@article{Ninatti2025,
  author = {Ninatti, Gaia and Scilipoti, Pietro and Pini, Cristiano and Barletta, Francesco and Longoni, Mattia and Gelardi, Fabrizia and Sollini, Martina and Gandaglia, Giorgio and Sathekge, Mike and Montorsi, Francesco and Chiti, Arturo and Briganti, Alberto},
  title = {Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {3386--3399},
  doi = {10.7150/thno.106574}
}
Kostenlos starten →